Literature DB >> 15179376

Comprehensive genetic and endoscopic evaluation may be necessary to distinguish sporadic versus familial adenomatous polyposis-associated abdominal desmoid tumors.

Prathap Bandipalliam1, Judith Balmana, Sapna Syngal.   

Abstract

BACKGROUND: There are limited data regarding how many patients with desmoid tumors actually represent cases with underlying familial adenomatous polyposis.
METHODS: A proband presenting with desmoid tumors and several of the family members underwent a detailed family history, genetic (adenomatous polyposis coli [APC] gene sequencing), and upper and lower endoscopic evaluation.
RESULTS: The proband's initial diagnosis was of a sporadic desmoid tumor. Colonoscopy was entirely normal. However, on subsequent esophagogastroduodenoscopy, several gastric polyps were found. The proband's mother subsequently underwent colonoscopy and was found to have multiple colon adenomas. On genetic analysis, a deletion of "T" was identified at codon 2645 of the APC gene in the proband. The proband's mother had a normal APC protein truncation test result. However, on full gene sequencing, the mother was found to harbor the same APC gene mutation.
CONCLUSION: A detailed family history and endoscopic and genetic evaluations for patients with desmoid tumors are vital because they may be the sentinel presentation of familial adenomatous polyposis. If confirmed in larger studies, APC full gene sequencing and upper and lower gastrointestinal tract evaluation may need to be part of standard evaluation of patients with abdominal desmoid tumors.

Entities:  

Mesh:

Year:  2004        PMID: 15179376     DOI: 10.1016/j.surg.2003.10.018

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  1 in total

1.  Yield of Colonoscopy in Identification of Newly Diagnosed Desmoid-Type Fibromatosis with Underlying Familial Adenomatous Polyposis.

Authors:  Winan J van Houdt; Iris H Wei; Deborah Kuk; Li-Xuan Qin; Bhumika Jadeja; Anthony Villano; Meera Hameed; Samuel Singer; Aimee M Crago
Journal:  Ann Surg Oncol       Date:  2019-01-04       Impact factor: 5.344

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.